Second, in view of limiting the first-line treatment to medications, treatment of schizophrenia cannot fully make
use of emerging knowledge about the etiological, neuropathological, and clinical nature of the illness and may therefore
fail to develop more effective treatments based on this new knowledge. With our current understanding of the molecular, functional, and pathophysiological nature of schizophrenia, new pharmacological and treatment approaches targeting specific stages of pathogenesis and groups of symptoms of the illness may prevent illness progression at different stages
and offer the possibility of personalized treatments based on an individual’s characteristics and illness condition.